Abstract:Accumulating evidences revealed that long noncoding RNAs (lncRNAs) have been participated in cancer malignant progression, including glioblastoma multiforme (GBM). Despite much studies have found the precise biological role in the regulatory mechanisms of GBM, however the molecular mechanisms, particularly upstream mechanisms still need further elucidated. RT-QPCR, cell transfection, western blotting and bioinformatic analysis were executed to detect the expression of EGR1, HNF1A-AS1, miR-22-3p and ENO1 in GBM. Cell proliferation assay, colony formation assay, wound healing, migration and invasion assays were performed to detect the malignant characters of GBM cells. The molecular regulation mechanism was confirmed by luciferase reporter assay, ChIP and RIP. Finally, orthotopic mouse models were established to examine the effect of HNF1A-AS1 in vivo. In the current study, we analyzed clinical samples to show that the HNF1A-AS1 expression is upregulated and associated with poor patient survival in GBM. Functional studies revealed that HNF1A-AS1 knockdown markedly inhibits malignant phenotypes of GBM cells, whereas overexpression of HNF1A-AS1 exerts opposite effect. Mechanistically, the transcription factor EGR1 forced the HNF1A-AS1 expression by directly binding the promoter region of HNF1A-AS1. Furthermore, combined bioinformatics analysis with our mechanistic work, using luciferase reporter assays and RIP, we first demonstrated that HNF1A-AS1 functions as a competing endogenous RNA (ceRNA) with miR-22-3p to regulate ENO1 expression in GBM cells. HNF1A-AS1 directly binds to miR-22-3p and significantly inhibits miR-22-3p expression, while ENO1 expression was increased. miR-22-3p inhibitor offsets the HNF1A-AS1 silencing induced suppression in malignant behaviors of GBM cells. ENO1 was verified as a direct target of miR-22-3p and its expression levels was negatively with the prognosis in GBM patients. Taken together, our study illuminated the definite mechanism of HNF1A-AS1 in promoting GBM malignancy, and provided a novel therapeutic target for further clinical application.

EN1 Regulates Cell Growth and Proliferation in Human Glioma Cells Via Hedgehog Signaling

Engrailed 2 (EN2) acts as a glioma suppressor by inhibiting tumor proliferation/invasion and enhancing sensitivity to temozolomide

Enolase-phosphatase 1 Acts As an Oncogenic Driver in Glioma.

EGR1 Modulated LncRNA HNF1A-AS1 Drives Glioblastoma Progression Via Mir-22-3p/eno1 Axis

Enolase1 Overexpression Regulates the Growth of Gastric Cancer Cells and Predicts Poor Survival

Inhibition of EGR1 Inhibits Glioma Proliferation by Targeting CCND1 Promoter

EEF1E1 Promotes Glioma Proliferation by Regulating Cell Cycle Through PTEN/AKT Signaling Pathway.

Enolase 1 Regulates Gastric Cancer Progression through the Electron Transfer Flavoprotein Dehydrogenase Gene

ENO1 contributes to the gemcitabine resistance of pancreatic cancer through the YAP1 signaling pathway

ENO1 Promotes Lung Cancer Metastasis via HGFR and WNT Signaling–Driven Epithelial-to-Mesenchymal Transition

ENO1 and Cancer

UAP1L1 plays an oncogene-like role in glioma through promoting proliferation and inhibiting apoptosis

ENO1 Contributes to Cell Proliferation and Invasion in Burkitt's Lymphoma

Dysregulated ENPP1 Increases the Malignancy of Human Lung Cancer by Inducing Epithelial-Mesenchymal Transition Phenotypes and Stem Cell Features.

RabGEF1 Functions As an Oncogene in U251 Glioblastoma Cells and is Involved in Regulating AKT and Erk Pathways

Abstract C114: Engrailed-1 promotes pancreatic cancer metastasis

Exploring the Role of ENO1 in Regulating Cell Proliferation and Cell Cycle in Hepatocellular Carcinoma: Insights from Proteomic Analysis

AEG-1 Expression Correlates with CD133 and PPP6c Levels in Human Glioma Tissues.

EN1 promotes lung metastasis of salivary adenoid cystic carcinoma by regulating the PI3K-AKT pathway and epithelial-mesenchymal transition

Enhydrin suppresses the malignant phenotype of GBM via Jun/Smad7/TGF-β1 signaling pathway

Data from ENO1 Promotes Lung Cancer Metastasis Via HGFR and WNT Signaling–Driven Epithelial-to-Mesenchymal Transition